Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 2—February 2019
Online Report

Public Health–Driven Research and Innovation for Next-Generation Influenza Vaccines, European Union

Adoración Navarro-TornéComments to Author , Finnian Hanrahan, Barbara Kerstiëns, Pilar Aguar, and Line Matthiessen
Author affiliations: European Commission Directorate-General for Research and Innovation, Brussels, Belgium

Main Article

Table 3

Opportunities in the development of the next-generation influenza vaccines

Faster manufacturing process
Continuous production: improving supply and stockpiling
Technology transfer to meet the implementation demand
Needle-free delivery systems
Lower implementation costs (doses, regimen, delivery)
Enhanced effectiveness in the elderly
Better uptake of the vaccine
Expanding influenza vaccine coverage in resource-poor settings
Indirect and generalized effects of the vaccine
Better arguments for advocacy and education of healthcare professionals and general public
Influenza pandemic preparedness planning
Age-personalized approach to vaccine development
Facilitating pandemic preparedness and response
One Health approach

Main Article

Page created: January 18, 2019
Page updated: January 18, 2019
Page reviewed: January 18, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.